Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1310

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Opevesostat
DRUG: Abiraterone acetate
DRUG: Enzalutamide
DRUG: Hydrocortisone
DRUG: Fludrocortisone acetate
DRUG: Prednisone
DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]